Gufic BioSciences Ltd

Gufic BioSciences Ltd

₹ 352 -0.97%
16 Jul - close price
About

Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

Key Points

History[1]
Gufic was in the business of manufacturing and marketing injectable products since late 1970s. The group had earlier exited its API and formulations manufacturing division by selling its six major brands such as Mox (Amoxycillin) Injection, Zole (Miconazole Nitrate) etc. to Ranbaxy in 1997. The promoters then re-entered pharmaceutical formulations segment through incorporation of Gufic Biosciences Limited in 2000.
Gufic Biosciences has been manufacturing lyophilized injectables (their main business) for 40+ years. It started with small base of 50,000 vials back in 2007-08 to right now almost 4 million vials per month.

  • Market Cap 3,532 Cr.
  • Current Price 352
  • High / Low 387 / 213
  • Stock P/E 41.0
  • Book Value 53.1
  • Dividend Yield 0.03 %
  • ROCE %
  • ROE %
  • Face Value 1.00

Pros

Cons

  • Stock is trading at 6.63 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024
215 202 195
176 165 161
Operating Profit 39 36 34
OPM % 18% 18% 18%
0 0 1
Interest 4 3 4
Depreciation 4 4 4
Profit before tax 31 30 27
Tax % 25% 25% 26%
23 22 20
EPS in Rs 2.39 2.22 2.00
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024
807
661
Operating Profit 146
OPM % 18%
2
Interest 15
Depreciation 17
Profit before tax 116
Tax % 26%
86
EPS in Rs 8.59
Dividend Payout % 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Stock Price CAGR
10 Years: 41%
5 Years: 39%
3 Years: 24%
1 Year: 64%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024
Equity Capital 10
Reserves 523
333
227
Total Liabilities 1,093
159
CWIP 307
Investments 2
625
Total Assets 1,093

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024
-7
-102
82
Net Cash Flow -27

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024
Debtor Days 149
Inventory Days 188
Days Payable 156
Cash Conversion Cycle 181
Working Capital Days 173
ROCE %

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
65.13% 75.48% 75.48% 75.48% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 72.51% 72.51%
0.14% 1.52% 1.69% 1.51% 1.38% 0.06% 0.16% 0.72% 0.70% 0.72% 0.47% 0.12%
3.24% 2.13% 1.19% 1.12% 1.13% 1.16% 1.16% 1.16% 1.16% 1.63% 1.72% 2.20%
31.49% 20.87% 21.64% 21.89% 22.49% 23.76% 23.67% 23.12% 23.12% 22.64% 25.29% 25.17%
No. of Shareholders 43,88335,13534,58038,14440,12041,37640,56238,90238,62436,55734,42434,695

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls